Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals
- PMID: 30653341
- DOI: 10.1152/ajpgi.00358.2018
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of conditions ranging from simple steatosis (NAFL), over nonalcoholic steatohepatitis (NASH) with or without fibrosis, to cirrhosis with end-stage disease. The hepatic molecular events underlying the development of NAFLD and transition to NASH are poorly understood. The present study aimed to determine hepatic transcriptome dynamics in patients with NAFL or NASH compared with healthy normal-weight and obese individuals. RNA sequencing and quantitative histomorphometry of liver fat, inflammation and fibrosis were performed on liver biopsies obtained from healthy normal-weight ( n = 14) and obese ( n = 12) individuals, NAFL ( n = 15) and NASH ( n = 16) patients. Normal-weight and obese subjects showed normal liver histology and comparable gene expression profiles. Liver transcriptome signatures were largely overlapping in NAFL and NASH patients, however, clearly separated from healthy normal-weight and obese controls. Most marked pathway perturbations identified in both NAFL and NASH were associated with markers of lipid metabolism, immunomodulation, extracellular matrix remodeling, and cell cycle control. Interestingly, NASH patients with positive Sonic hedgehog hepatocyte staining showed distinct transcriptome and histomorphometric changes compared with NAFL. In conclusion, application of immunohistochemical markers of hepatocyte injury may serve as a more objective tool for distinguishing NASH from NAFL, facilitating improved resolution of hepatic molecular changes associated with progression of NAFLD. NEW & NOTEWORTHY Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. NAFLD is associated with the metabolic syndrome and can progress to the more serious form, nonalcoholic steatohepatitis (NASH), and ultimately lead to irreversible liver damage. Using gold standard molecular and histological techniques, this study demonstrates that the currently used diagnostic tools are problematic for differentiating mild NAFLD from NASH and emphasizes the marked need for developing improved histological markers of NAFLD progression.
Keywords: histomorphometry; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; transcriptomics.
Similar articles
-
Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Gene. 2020 Jun 5;742:144549. doi: 10.1016/j.gene.2020.144549. Epub 2020 Mar 14. Gene. 2020. PMID: 32184169
-
Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.Ann Hepatol. 2020 Sep-Oct;19(5):472-481. doi: 10.1016/j.aohep.2020.06.009. Epub 2020 Jul 15. Ann Hepatol. 2020. PMID: 32682086
-
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18. Adv Exp Med Biol. 2024. PMID: 39287864 Review.
-
The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Am J Physiol Gastrointest Liver Physiol. 2020 Sep 1;319(3):G345-G360. doi: 10.1152/ajpgi.00055.2020. Epub 2020 Aug 5. Am J Physiol Gastrointest Liver Physiol. 2020. PMID: 32755310 Free PMC article.
-
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.Transplantation. 2019 Jan;103(1):e1-e13. doi: 10.1097/TP.0000000000002480. Transplantation. 2019. PMID: 30300287 Review.
Cited by
-
Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug development.Sci Rep. 2024 Oct 7;14(1):23362. doi: 10.1038/s41598-024-74098-w. Sci Rep. 2024. PMID: 39375498 Free PMC article.
-
Overlooked poor-quality patient samples in sequencing data impair reproducibility of published clinically relevant datasets.Genome Biol. 2024 Aug 16;25(1):222. doi: 10.1186/s13059-024-03331-6. Genome Biol. 2024. PMID: 39152483 Free PMC article.
-
Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease.Nat Commun. 2023 Mar 17;14(1):1474. doi: 10.1038/s41467-023-37209-1. Nat Commun. 2023. PMID: 36927865 Free PMC article.
-
Characterization of regulatory transcriptional mechanisms in hepatocyte lipotoxicity.Sci Rep. 2022 Jul 7;12(1):11477. doi: 10.1038/s41598-022-15731-4. Sci Rep. 2022. PMID: 35798791 Free PMC article.
-
The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm.Am J Physiol Gastrointest Liver Physiol. 2022 Oct 1;323(4):G387-G400. doi: 10.1152/ajpgi.00130.2022. Epub 2022 Aug 23. Am J Physiol Gastrointest Liver Physiol. 2022. PMID: 35997288 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases